AIM ImmunoTech says Ampligen combo posts 50% response rate in ovarian cancer trial

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc. Common Stock

AIM

0.00
  • AIM ImmunoTech reported final primary endpoint results from a UPMC-run Phase 2 trial in recurrent ovarian cancer testing Ampligen in combination with a checkpoint inhibitor and chemotherapy.
  • Results have already been presented in a final primary endpoint report.
  • Patients showed a high level of tumor shrinkage, including complete remissions in some cases, with responses that were durable in select patients.
  • Safety profile appeared favorable, with no most-severe treatment-related toxicities reported.
  • Additional follow-up analyses, including survival-related endpoints, are scheduled for completion in January 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070823PRIMZONEFULLFEED9714973) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.